Zenas BioPharma, Inc. (ZBIO) - What Are Analysts Thinking About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Nine analysts give Zenas BioPharma a “Moderate Buy” consensus, with six buys, two holds and one sell. The average 12-month price target is $46.71, well above the reported $27.26 share price.
• The company reported weaker-than-expected quarterly results: Zenas posted an adjusted loss of $1.77 per share versus the $1.12 consensus estimate and generated $1 million in revenue, below analysts’ $15 million forecast.
• Zenas is a clinical-stage autoimmune-drug developer: Its lead candidate, obexelimab, is designed to suppress B-cell activity without eliminating B cells, while major institutional investors including BlackRock and Wellington have built or increased positions.

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $46.71.

Several equities analysts recently issued reports on ZBIO shares. Weiss Ratings restated a "sell (e+)" rating on shares of Zenas BioPharma in a report on Tuesday, October 6th. Wedbush reiterated an "outperform" rating and set a $45.00 price target on shares of Zenas BioPharma in a report on Wednesday, September 30th. HC Wainwright reissued a "buy" rating and issued a $44.00 price objective on shares of Zenas BioPharma in a research report on Wednesday, September 30th. Citigroup lifted their price objective on Zenas BioPharma from $41.00 to $48.00 and gave the stock a "buy" rating in a research report on Wednesday, September 30th. Finally, Morgan Stanley boosted their price objective on Zenas BioPharma from $22.00 to $32.00 and gave the company an "equal weight" rating in a research note on Friday, August 14th.

Zenas BioPharma Price Performance

Zenas BioPharma stock opened at $27.26 on Monday. The stock's 50 day moving average is $30.81 and its 200 day moving average is $25.33. The company has a debt-to-equity ratio of 1.57, a current ratio of 9.93 and a quick ratio of 9.93. The firm has a market cap of $1.78 billion, a P/E ratio of -3.03 and a beta of -0.90. Zenas BioPharma has a one year low of $13.50 and a one year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $15.00 million. As a group, research analysts expect that Zenas BioPharma will post -5.81 EPS for the current year.

Institutional Investors Weigh In On Zenas BioPharma

Several large investors have recently added to or reduced their stakes in ZBIO. BlackRock Inc. acquired a new stake in shares of Zenas BioPharma during the 2nd quarter worth approximately $68,176,000. Wellington Management Group LLP increased its stake in shares of Zenas BioPharma by 27.9% in the 2nd quarter. Wellington Management Group LLP now owns 1,593,819 shares of the company's stock valued at $40,451,000 after acquiring an additional 347,766 shares in the last quarter. Polar Capital Holdings Plc bought a new stake in shares of Zenas BioPharma in the 4th quarter valued at $38,402,000. Bank of America Corp DE acquired a new position in shares of Zenas BioPharma during the 2nd quarter valued at $31,247,000. Finally, EcoR1 Capital LLC acquired a new position in shares of Zenas BioPharma during the 4th quarter valued at $28,667,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company's research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas' lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.